Industry picks holes in US guidance on expedited drug review programs
This article was originally published in SRA
Executive Summary
A draft guidance document on four expedited review programs available at the US Food and Drug Administration for medicines for serious conditions fails to address adequately a fifth expedited process. In addition, the text omits to mention rare diseases and does not explain how relevant companion diagnostics are to be reviewed in time1-3.